• Bavarian Nordic’s third-quarter 2026 net profit fell 59% year over year to DKK 446.92 million.
• Revenue rose to DKK 1.8 billion, while Travel Health revenue climbed 22% year over year to DKK 1.14 billion.
• A four-year UK government contract awarded in November covers supplies of the MVA-BN mpox and smallpox vaccine.
• Full-year 2026 revenue guidance remained approximately DKK 6.1 billion, maintaining the outlook upgraded October 8.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bavarian Nordic A/S published the original content used to generate this news brief on November 13, 2026, and is solely responsible for the information contained therein.